실적분석 2026년 8월 3일

TG Therapeutics ($TGTX) Q2 2026 Earnings Analysis — Revenue Beat and Raised Annual Guidance Despite After-Hours Weakness

Earnings Scorecard

Revenue: $240 million (year-over-year +70%, estimate $230 million) ✅ Beat

EPS: GAAP diluted $0.05 (prior-year $0.17) · Not directly comparable to adjusted estimate $0.44 due to differing accounting bases

Guidance: Raised — 2026 full-year total revenue target of about $950 million; Briumvi U.S. net product revenue of about $890–$905 million

Stock reaction: After-hours -3.92% ($49.99) — as of 08-03 20:46 Korea time

Positives

Revenue beat: Q2 total revenue of $240 million topped the $230 million estimate

Briumvi growth: U.S. net product revenue of $228 million, up about 64% year-over-year

Raised full-year targets: 2026 total revenue and U.S. net product revenue guidance both lifted higher

Multiple sclerosis therapy Briumvi (BRIUMVI) was the centerpiece of the results. On top of Q2 U.S. net product revenue of $227.7 million, total product revenue—including shipments to ex-U.S. partners and other items—reached $235.8 million, and total revenue including royalties and other income came in at $240.3 million, up roughly 70% from $141.1 million a year earlier.

The company raised its full-year total revenue target to about $950 million and its Briumvi U.S. net product revenue target to about $890–$905 million. The CEO expressed confidence that annualized U.S. Briumvi revenue could reach a run-rate of roughly $1 billion by the end of 2026.

The clinical pipeline was also strengthened. The Phase 3 ENHANCE trial, designed to simplify the dosing initiation regimen, hit its primary endpoint, alongside Phase 1 subcutaneous formulation data and announcements of expansion into myasthenia gravis and treatment-resistant schizophrenia.

Negatives

Sharp drop in net income: Q2 net income of $7.8 million, a steep decline from $28.2 million a year earlier

R&D surge: R&D expense of $95.3 million (versus $31.8 million a year ago), including costs related to subcutaneous formulation manufacturing

Earnings quality weakened: GAAP diluted EPS of $0.05, retreating from $0.17 a year ago

Revenue grew sharply, but profitability moved in the opposite direction. Q2 2026 net income came in at $7.8 million, far below the $28.2 million posted a year earlier. Over the same period, GAAP diluted EPS also fell to $0.05 from $0.17 a year ago. Because the calculation methodology differs from the adjusted estimate ($0.44) used by the market, the print cannot be labeled a straightforward "miss" based on the headline alone—but the deterioration in earnings quality is clear.

Costs weighed heavily on results. R&D expense ballooned to about $95.3 million, nearly triple the prior-year level, with roughly $54.6 million of that tied to subcutaneous Briumvi manufacturing and second manufacturing site ramp-up costs alone. Selling, general and administrative expense also climbed to about $82.1 million on expanded marketing and headcount.

Full-year operating expense guidance added to the burden. The company set combined R&D and SG&A, excluding stock-based compensation, at about $350–$400 million, and layered on roughly $100 million in additional costs for subcutaneous manufacturing and second manufacturing site ramp-up. While the company remains in a growth-investment phase, the pace of earnings recovery may be limited.

What Management Said

Management framed the quarter as "another strong quarter," emphasizing that Briumvi's commercial performance once again outpaced company expectations. The tone placed greater weight on the message of scaling annualized U.S. Briumvi revenue to roughly $1 billion and broadening the long-term growth pillars—through improved dosing convenience, the subcutaneous formulation, and new indications—rather than on near-term numbers.

The guidance update was centered on revenue. No profit targets or EPS outlooks were provided, and management acknowledged that R&D and commercialization costs would remain elevated for the time being. From the market's perspective, the mix reads easily as "revenue raised, profits in an investment phase." Cash and marketable securities stood at about $612 million as of the end of June, which the company said is sufficient to fund operations under its current plans.

Market Reaction and What to Watch Next

Despite the headline positives of a revenue beat and raised full-year guidance, the stock traded lower after hours. Commercial growth appears to have already been largely priced in, while the year-over-year drop in net income driven by R&D and manufacturing investment seems to have weighed more heavily on sentiment. The dominant read on the tape is "growth confirmed, earnings quality still in question."

Whether Briumvi's U.S. net product revenue growth streak continues into Q3, keeping the path to a $1 billion annualized run-rate by year-end intact, needs to be confirmed.

Key dates to monitor include the Phase 3 subcutaneous Briumvi topline readout (expected late 2026 to early 2027) and the detailed results disclosure timeline for the Phase 3 ENHANCE trial.

Investors will need to gauge when subcutaneous manufacturing and second manufacturing site costs pass their peak, allowing operating profit to improve again.